Advanced epithelial ovarian cancer
Conditions
Interventions
Experimental group:CRS + HIPEC 3 times + TC regimen intravenous chemotherapy for 6 cycles
Control group:CRS+TC regimen intravenous chemotherapy for 6 cycles
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Primary epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer at stage III at the time of diagnosis, and no other anti-tumor therapy such as chemotherapy or radiotherapy was performed before the start of the clinical trial; 2. Residual lesions in the abdominal cavity =3.0x10^9/L, neutrophil >= 1.5x10^9/L, platelet count >= 100 x 10^9/L, hemoglobin >= 80 g/L; 6. The organ function is good, and the biochemical examination meets the following conditions: AST <= 2.5xUpper limit of normal value (ULN), ALT <= 2.5xUpper limit of normal value (ULN), serum total bilirubin<=1.5xupper limit of normal (ULN), creatinine<=1.5xupper limit of normal (ULN); 7. Functional status: 0-1 (ECOG); 8. The informed consent of the patient has been obtained.
Exclusion criteria
Exclusion criteria: 1. Extensive adhesions in the abdominal cavity; 2. Patients with other malignant tumors (excluding skin cancer and thyroid cancer) within 5 years; 3. At the same time have other serious diseases that are difficult to control (including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction less than 50%, refractory hypertension, renal insufficiency, uncontrollable infection, etc.); 4. Being treated with anticancer drugs in other clinical trials; 5. Any unstable condition or situation that may jeopardize patient safety and compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine and liver and kidney function tests;Tumor markers;Imaging examination (CT or MRI of abdomen and pelvis, chest X-ray); | — |
Countries
China
Contacts
Public ContactZhou Dan
Beijing Hospital
Outcome results
None listed